

## 6. Literaturverzeichnis

---

- 1 Pavesio CE, Lightman S. Toxoplasma gondii and ocular toxoplasmosis: pathogenesis. Br J Ophthalmol 1996;80:1099-1107.
- 2 Henderly DE, Gentsler AJ, Smith RE, Rao NA. Changing patterns of uveitis. Am J Ophthalmol 1987;103:131-136.
- 3 Nicolle C, Manceaux L. Sur un protozoaire nouveau du gondi, Toxoplasma. Arch Inst Pasteur Tunis 1909;2:97-103.
- 4 Splendore A. Uno nuovo protozoa parasite die conigli: incontrato nelle lesioni anatomiche d'una malattia che ricorda in molti punti il Kala-azar dell'uomo. Rev Soc Sci Sao Paolo 1908;3:109-112.
- 5 Mine N. Observation on protozoan parasites in Japan. Gun-I-Dan Zasshi 1911;27:1.
- 6 Darling ST. Sarcosporidiosis: with report of a case in man. Proc Canal Zone Med Assoc 1908;1:141-5.
- 7 Janku J. Die pathogenese und pathologische anatomie des sogenannten angeborenen koloboms des gelben flecks im normal grossen sowie mikrophthalmischen auge mit parasitenbefund in der netzhaut. Cts Parasit 1959;6:9-16.
- 8 Wolf A, Cowen D, Paige BH. Human toxoplasmosis. Occurrence in infants as an encephalomyelitis. Verification by transmission to animals. Science 1939;89:226.
- 9 Remky H. Toxoplasmosis. Argumenta et documenta ophthalmologica. J. F. Lehmanns Verlag, München, 1962.

- 
- 10 Molzberger S. Untersuchungen zur Epidemiologie, Diagnose und Therapie der Toxoplasmose unter besonderer Berücksichtigung der Augenbeteiligung. Med. Dissertation, TU-München, 2002.
- 11 Frenkel JK. Dermal hypersensitivity to toxoplasma antigens (toxoplasmins). Proc Soc Exp Biol Med 1948;68:634-639.
- 12 Wilder HC. Toxoplasma chorioretinitis in adults. Arch Ophthalmol 1952;47:425-438.
- 13 Weinman D, Chandler AH. Toxoplasmosis in man and swine - an investigation of the possible relationship. JAMA 1956;161:229-232.
- 14 Hutchison WM. Experimental transmission of *Toxoplasma gondii*. Nature 1965;206:961-962.
- 15 Weiland H, Kühn D. Experimentelle Toxoplasma-Infektionen bei der Katze. II. Entwicklungsstadien des Parasiten im Darm. Berl Münch Tierärztl Wochenschr 1970;83:128-132.
- 16 Frenkel JK, Dubey JP, Miller NL. *Toxoplasma gondii* in cats: fecal stages identified as coccidian oocysts. Science 1970;167:893-6.
- 17 Hutchison WM, Dunachie JF, Siim JC, Work K. Coccidian-like nature of *Toxoplasma gondii*. BMJ 1970;1:142-144.
- 18 Montoya JG, Liesenfeld O. Toxoplasmosis Lancet 2004;363:1965-76.
- 19 Howe DK, Sibley DL. *Toxoplasma gondii* comprises three clonal lineages: correlation of parasite genotype with human disease. J Infect Dis 1995;172:1561-66.

- 
- 20 Ajzenberg D, Cogne N, Paris L, et al. Genotype of 86 *Toxoplasma gondii* isolates associated with human congenital toxoplasmosis, and correlation with clinical findings. *J Infect Dis* 2002;186:684–89.
- 21 Seitz HM. *Toxoplasma gondii*: Mikrobiologische Aspekte. In: "Toxoplasmose - Erreger und Krankheit", Pohle, H. D.; Remington, J. S. (Hrsg.), 2. Auflage Socio-medico Verlag, Gräfelfing, 1995:43-52.
- 22 Remington JS, McLeod R. Toxoplasmosis. In: "Infectious Diseases and Medical Microbiology", Braude, A. I.; Davis, C. E.; Fierer, J. (eds.), 2nd edition. W. B. Saunders Company, Philadelphia, London, Toronto, 1986:1521-1535.
- 23 Wildführ W. Der Erreger der Toxoplasmose - *Toxoplasma gondii* Nicolle und Manceaux 1908. In: "Toxoplasmose. Ratgeber für Ärzte und Tierärzte", Wildführ, G.; Wildführ, W. (Hrsg.), 1. Auflage, VEB Gustav Fischer Verlag, Jena, 1975:15-45.
- 24 Jacquier P, Deplazes P, Heimann P, Gottstein B. Parasitologie und humanmedizinisch-präventive Bedeutung von *Toxoplasma gondii*. *Schweiz Med Wochenschr* 1995;65:10-18.
- 25 Kayser FH, Bienz. "Medizinische Mikrobiologie" Georg Thieme Verlag, Stuttgart, New York, 1989; 9. Auflage.
- 26 Dubey, J. P.; Beatie, C. P. Toxoplasmosis of animal and man. Boca Raton: CRP Press, 1988; 220.
- 27 Stray-Pedersen B, Jenum P. Current status of toxoplasmosis in pregnancy in Norway. *Scand J Infect Dis* 1992;84:80-83.
- 28 Zuber P, Jacquier P. Epidémiologie de la toxoplasmose: situation au niveau mondial. *Schweiz Med Wochenschr* 1995;125:19-22.

- 
- 29 Daffos F, Forestier F, Capella-Pavlovsky M, et al. Prenatal management of 746 pregnancies at risk for congenital toxoplasmosis. *N Engl J Med* 1988;318:271-275.
- 30 Janitschke K. Toxoplasmose. In: "Medizinische Mikrobiologie", Hahn, H.; Falke, D.; Klein, P. (Hrsg.), Springer Verlag, Berlin, Heidelberg, New York, 1991:898-900.
- 31 Reis e Sousa C, Hieny S, Scharon-Kersten T, et al. In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas. *J Exp Med* 1997;198:1819–29.
- 32 Denkers EY, Gazzinelli RT. Regulation and function of T-cell mediated immunity during *Toxoplasma gondii* infection. *Clin Microbiol Rev* 1998;11:569–88.
- 33 Liesenfeld O, Wong SY, Remington JS. Toxoplasmosis in the setting of AIDS. In: Bartlett JG, Merigan TC, Bolognesi D, eds. *Textbook of AIDS medicine*, 2nd ed. Baltimore: Williams & Wilkins, 1999:225–59.
- 34 Ronday MJ, Stilma JS, Barbe RF, et al. Aetiology of uveitis in Sierra Leone, West Africa. *Br J Ophthalmol* 1996;80:956-961.
- 35 Tran VT, Auer C, Guex-Crosier Y, Pittet N, Herbort CP. Epidemiological characteristics of uveitis in Switzerland. *Int Ophthalmol* 1994;18:293-298.
- 36 Maetz HM, Kleinstein RN, Federico D, Wayne J. Estimated prevalence of ocular toxoplasmosis and toxocariasis in Alabama. *J Infect Dis* 1987;156:414.
- 37 Gilbert RE, Stanford MR, Jackson H, Holliman RE, Sanders MD. Incidence of acute symptomatic toxoplasma retinochoroiditis in south London according to country of birth. *BMJ* 1995;310:1037-1040.
- 38 Holland GN. Ocular Toxoplasmosis: A Global Reassessment Part II: Disease Manifestations and Management *Am J Ophthalmol* 2004;137:1-17.

---

39 Holland GN, O'Connor GR, Belfort R, Remington JS. Toxoplasmosis. In: Pepose JS, Holland GN, Wilhelmus KR, editors. Ocular infection & immunity. St. Louis, Missouri: Mosby-Year Book, Inc., 1996:1183–1223.

40 Whittle RM, Wallace GR, Whiston RA, Dumonde DC, Stanford MR. Human antiretinal antibodies in toxoplasma retinochoroiditis. *Br J Ophthalmol* 1998;82:1017-21.

41 Bosch-Driessen EH, Rothova A. Sense and nonsense of corticosteroid administration in the treatment of ocular Toxoplasmosis *Br J Ophthalmol* 1998;82:858-860.

42 Holliman RE, Stevens PJ, Duffy KT, Johnson JD. Serological investigation of ocular toxoplasmosis. *Br J Ophthalmol* 1991;75:353-355.

43 Goldmann H, Witmer R. Antikörper im Kammerwasser. *Ophthalmologica* 1957;127:323-330.

44 Witmer RH. Ätiologische Diagnostik der Uveitis. *Graefes Arch Clin Exp Ophthalmol* 1955;156:235-260.

45 Engstrom RE, Holland GN, Nussenblatt RB, Jabs DA. Current practices in the management of ocular toxoplasmosis. *Am J Ophthalmol* 1991;111:601-610.

46 Georgiev VS. Management of toxoplasmosis. *Drugs* 1994;48:179-188.

47 Rothova A, Meenken C, Buitenhuis HJ, et al. Therapy for ocular toxoplasmosis. *Am J Ophthalmol* 1993;115:517-523.

48 Holland GN, Lewis KG. An update on current practices in the management of ocular toxoplasmosis. *Am J Ophthalmol* 2002;134:102-114.

- 
- 49 Hartmann C, Hanssen C, Felgenhauer K. Filtration und lokale Synthese von Proteinen im Kammerwasser und Liquor cerebrospinalis. *Fortschr Ophthalmol* 1983;80:103-107.
- 50 Joynton DH. Epidemiology of toxoplasmosis in the U.K. *Scand J Infect Dis* 1992;84:65-69.
- 51 Jones JL, Kruszon-Moran D, Wilson M, McQuillan G, Navin T, McAuley JB. Toxoplasma gondii infection in the United States: seroprevalence and risk factors. *Am J Epidemiol* 2001;154:357-65.
- 52 Forsgren M, Gille E, Ljungstrom I, Nokes DJ. Toxoplasma gondii antibodies in pregnant women in Stockholm in 1969, 1979, and 1987. *Lancet* 1991;337:1413-14.
- 53 Smith KL, Wilson M, Hightower AW, et al. Prevalence of Toxoplasma gondii antibodies in US military recruits in 1989: comparison with data published in 1965. *Clin Infect Dis* 1996;23:1182-83.
- 54 Paivonsalo HT, Tuominen J, Vaahtoranta LH, et al. Incidence and prevalence of different uveitis entities in Finland. *Acta Ophthalmol Scand* 1997;75:76-81.
- 55 Chowdhury MN. Toxoplasmosis: a review. *J Med* 1986;17:373-396.
- 56 Smit R, Baarsma GS, Vries J. Classification of 750 consecutive uveitis patients in the Rotterdam Eye Hospital. *Int Ophthalmol* 1993;17:71-75.
- 57 Perkins ES, Folk J. Uveitis in London and Iowa. *Ophthalmologica* 1984;189:36-40.
- 58 Gilbert RE, Dunn DT, Lightman S, et al. Incidence of symptomatic toxoplasma eye disease: aetiology and public health implications. *Epidemiol Infect* 1999;123:283-9.

- 
- 59 Glasner PD, Silveira C, Kruszon-Moran D, et al. An unusually high prevalence of ocular toxoplasmosis in Southern Brazil. *Am J Ophthalmol* 1992;114:136-144.
- 60 Chapman DJ, Ashburn D, Ogston SA, Ho-Yen DO. The relationship between ocular toxoplasmosis and levels of specific *Toxoplasma* antibodies. *Epidemiol Infect* 1999;122:299-303.
- 61 Hogan MJ. Ocular toxoplasmosis in adult patients. *Surv Ophthalmol* 1961;6:935-951.
- 62 Gilbert RE, Stanford MR. Is ocular toxoplasmosis caused by prenatal or postnatal infection? *Br J Ophthalmol* 2000;84:224-6.
- 63 Guerina NG, Hsu HW, Meissner HC, et al. Neonatal serological screening and early treatment for congenital *Toxoplasma gondii* infection. *N Engl J Med* 1994;330:1858-63.
- 64 Dunn D, Wallon M, Peyron F, et al. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. *Lancet* 1999;353:1829-33.
- 65 Lebech M, Andersen O, Christensen NC, et al. Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment. Danish Congenital Toxoplasmosis Study Group. *Lancet* 1999;353:1834-7.
- 66 Koppe JG, Loewer-Sieger DH, de Roever-Bonnet H. Results of 20-year follow-up of congenital toxoplasmosis. *Lancet* 1986;1:254-6.
- 67 Burnett AJ, Shortt SG, Isaac-Renton J, et al. Multiple cases of acquired toxoplasmic retinitis presenting in an outbreak. *Ophthalmology* 1998;105:1032-7.
- 68 Perkins ES. Ocular toxoplasmosis. *Br J Ophthalmol* 1973;57:1-17.

---

69 Mittelviehhaus, H. Toxoplasmose in der Augenheilkunde. In: "Infektionen durch Toxoplasma gondii", Shah, P. M.; Stille, W. (Hrsg.), 2. Auflage, Socio-medico Verlag, Gräfelfing, 1992:53-64.

70 Fish RH, Hoskins JC, Kline LB. Toxoplasmosis neuroretinitis. *Ophthalmology* 1993;100:1177-1182.

71 Bosch-Driessen LE, Berendschot TT, Ongkosuwito JV, Rothova A. Ocular toxoplasmosis: clinical features and prognosis of 154 patients. *Ophthalmology* 2002;109:869-878.

72 Smith JR, Cunningham ET. Atypical presentations of ocular toxoplasmosis. *Curr Opin Ophthalmol* 2002;13:387-392.

73 Folk JC; Lobes LA. Presumed toxoplasmic papillitis. *Ophthalmology* 1984;91:64-67.

74 Hayashi S, Kim MK, Belfort R. White-centered retinal hemorrhages in ocular toxoplasmosis. *Retina* 1997;17:351-352.

75 Gaynon MW, Boldrey EE, Strahlman ER, Fine SL. Retinal neovascularization and ocular toxoplasmosis. *Am J Ophthalmol* 1984;98:585-589.

76 Quentin CD, Reiber H. Kammerwasseranalytik bei intraokularer Toxoplasmose. *Ophthalmologe* 1997;94:728-731.

77 Janitschke, K. Stand der Serodiagnostik der Toxoplasma-Infektion in der Schwangeren- und Kindervorsorge. In: "Toxoplasmose - Erreger und Krankheit", Pohle, HD, Remington JS. (Hrsg.), 2. Auflage, Socio-medico Verlag, Gräfelfing, 1995:112-121.

78 Damms T, Böhnke M, Behrend-Berdin B, Laufs R. Antikörpertiter gegen Toxoplasma gondii bei Uveitiden toxoplasmotischer und anderer Genese. *Fortschr Ophthalmol* 1991;88:154-157.



---

79 Garweg JG, Jacquier P, Boehnke M. Early aqueous humor analysis in patients with human ocular toxoplasmosis. *J Clin Microbiol* 2000;38:996-1001.

80 Ongkosuwito JV, Bosch-Driessen EH, Kijlstra A, Rothova A. Serologic evaluation of patients with primary and recurrent ocular toxoplasmosis for evidence of recent infection. *Am J Ophthalmol* 1999;128:407-12.

81 Ronday MJH, Luyendijk L, Baarsma GS, Bollemeijer JG, Van der Lelij A, Rothova A. Presumed acquired ocular toxoplasmosis. *Arch Ophthalmol* 1995;113:1524-1529.

82 Desmots, G. Toxoplasmose oculaire: Etude épidémiologique (bilan de 2030 examens d'humeur aqueuse). *Arch Ophthalmol* 1973;33:87-102.

83 Liekfeld A, Schweig F, Jaeckel C, Wernecke KD, Hartmann C, Pleyer U. Intraocular antibody production in intraocular inflammation. *Graefes Arch Clin Exp Ophthalmol* 2000;238: 222-7.

84 de Abreu ML, Belfort R, Hirata PS. Fuchs' heterochromic cyclitis and ocular toxoplasmosis. *Am J Ophthalmol* 1982;93:739-744.

85 Pleyer U, Mondino BJ, Adamu SA, Pitchekian-Halabi H, Engstrom RE, Glasgow BJ. Immune response to *Staphylococcus epidermidis*-induced endophthalmitis in a rabbit model. *Invest Ophthalmol Vis Sci* 1992;33:2650-2663.

86 Abe T, Tsuchida K, Tamai M. A comparative study of the polymerase chain reaction and local antibody production in acute retinal necrosis syndrome and cytomegalovirus retinitis. *Graefes Arch Clin Exp Ophthalmol* 1996;234:419-424.

87 Garweg J, Böhnke M, Körner F. Restricted applicability of the polymerase chain reaction for the diagnosis of ocular toxoplasmosis. *Ger J Ophthalmol* 1996;5:104-108.

---

88 de Boer JH, Verhagen C, Bruinenberg M, et al. Serologic and polymerase chain reaction analysis of intraocular fluids in the diagnosis of infectious uveitis. *Am J Ophthalmol* 1996;121:650-658.

89 Montoya JG, Parmley S, Liesenfeld O, Jaffe GJ, Remington JS. Use of the Polymerase Chain Reaction for Diagnosis of Ocular Toxoplasmosis. *Ophthalmology* 1999;106:1554-1563.

90 Stanford MR, See SE, Jones LV, Gilbert RE. Antibiotics for toxoplasmic retinochoroiditis: an evidence-based systematic review. *Ophthalmology* 2003;110:926-31.

91 Perkins ES, Smith CH, Schofield PB. Treatment of Uveitis with pyrimethamine (Daraprim). *Br J Ophthalmol* 1956;40:577-86.

92 Silveira C, Belfort R, Muccioli C, et al. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. *Am J Ophthalmol* 2002;134:41-6.

93 Acers TE. Toxoplasmic retinochoroiditis: a double blind therapeutic study. *Arch Ophthalmol* 1964;71:58-62.

94 Lakhanpal V, Schocket SS, Nirankari VS. Clindamycin in the treatment of toxoplasmic retinochoroiditis. *Am J Ophthalmol* 1983;95:605-613.

95 Tabbara KF, O'Connor GR. Treatment of ocular toxoplasmosis with clindamycin and sulfadiazine. *Ophthalmology* 1980;87:129-134.

96 Tabbara KF, O'Conner GR. Ocular tissue absorption of clindamycin phosphate. *Arch Ophthalmol* 1975;93:1180-5.

---

97 Kaufman HE. The penetration of daraprim (pyrimethamine) into monkey eye. *Am J Ophthalmol* 1961;52:402-4.

98 Reeves DS, Wilkinson PJ. The pharmacokinetics of trimethoprim and trimethoprim /sulphonamide combinations, including penetration into body tissues. *Infection* 1979;7:330-41.

99 Pfefferkorn ER, Nothnagel RF, Borotz SE. Parasitocidal effect of clindamycin on *Toxoplasma gondii* grown in cultured cells and selection of a drug-resistant mutant. *Antimicrob Agents Chemother* 1992;36:1091-1096.

100 Tabbara KF, Dy-Liacco J, Nozik RA, O'Conner GR, Blackman J. Clindamycin in chronic toxoplasmosis. Effect of periocular injection on recoverability of organisms from healed lesions in the rabbit eye. *Arch Ophthalmol* 1979;97: 542-4.

101 Araujo FG, Remington JS. Effect of clindamycin on acute and chronic toxoplasmosis in mice. *Antimicrob Agents Chemother* 1974;5:647-51.

102 Kishore K, Conway MD, Peyman GA. Intravitreal clindamycin and dexamethasone for toxoplasmic retinochoroiditis. *Ophthalmic Surg Lasers* 2001;32:183-92.

103 Hacker M, Richter R, Gumbel H, Richter T, Ohrloff C. Toxoplasmosis retinochorioiditis, a therapy comparison between spiramycin and pyrimethamine/sulfadiazine. *Klin Monatsbl Augenheilkd* 1998;212:84-7.

104 Rothova A, Bosch-Driessen LEH, van Loon NH, Treffers WF. Azithromycin for ocular toxoplasmosis. *Br J Ophthalmol* 1998;82:1306-1308.

105 Kovacs JA. Intramural AIDS-Program Efficacy of atovaquone in treatment of toxoplasmosis in patient with AIDS. *Lancet* 1992;340:637-638.

---

106 Hudde T, Althaus C, Schimkat M, Sundmacher R. Behandlung der Toxoplasmose-Retinochorioiditis mit Atovaquon bei immunkompetenten Patienten. *Klin Monatsbl Augenheilkd* 1996;209:232-236.

107 Araujo FG, Huskinson-Mark J, Gutteridge WE, Remington JS. In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of *Toxoplasma gondii*. *Antimicrob Agents Chemother* 1992;36: 326-330.

108 Pearson PA, Piracha AR, Sen HA, Jaffe GJ. Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients. *Ophthalmology* 1999;106:148-53.

109 Sumyuen MH, Garin YJF, Derouin F. Effect of immunosuppressive drug regimens on acute and chronic murine toxoplasmosis. *Parasitol Res* 1996;82:681-6.

110 Hofflin JM, Conley FK, Remington JS. Murine model of intracerebral toxoplasmosis. *J Infect Dis* 1987;155:550-6.

111 Kaufman HE. The effect of corticosteroids on experimental ocular toxoplasmosis. *Am J Ophthalmol* 1960;50:919-25.